|Day Low/High||63.75 / 64.35|
|52 Wk Low/High||63.22 / 80.02|
Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.
I believe this president goes full Trumpian tonight, in a style that he has made all his own.
The pharmaceutical distributor is finally turning around.
It used the earning's call to pass much of the blame for high drug prices onto pharmaceutical companies.
The country's largest pharmacy benefits manager is enjoying tailwinds after reporting a big jump in year-over-year profits.
The pharmacy benefit manager shifted blame for drug pricing back to pharma companies.
Kaleo's EpiPen compeitor the Auvi-Q was released today.
The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.
BLL, OPK, ESRX, SKYW and DLA all were recently downgraded by TheStreet's Quant Ratings.
Jim Cramer likes European banks, plus Banco Santander, and New York Community Bancorp, too.
Jim Cramer takes a closer look at the risks: Don't measure 'Trump per share,' measure actual earnings per share.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AG, AMZN, CBPX, CTLT, FSM, GOLD, LADR, OHI Downgrades: ESRX, GCO, NXPI, OPB, PIP, RDY, TM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
The most ethnically and gender diverse boards may surprise you.
- Patients' share of cost for prescription drugs declined for the second consecutive year
The comparison to the New York mob boss was only the beginning of Citron Research's inflammatory comments
Real Money contributor Stephen Guilfoyle sees some reasons for caution in stock trading right now.
It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.
The combination of the insurance giants was found to be a threat to competition.
The stock has taken a beating, but users of Afrezza are loyal to the drug.
A study of analyst recommendations at the major brokerages shows that Express Scripts Holding Co is the #84 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Kass' trade of the year for 2017 is to short the PowerShares QQQ Trust ETF.